Vection secures $1.2m in non-dilutive government grant funding for AI and XR programs
Vection Technologies (ASX: VR1, OTC: VCTNY, FRA: S1X) has received $1.2 million in cash from Government R&D Programs as non-repayable, non-dilutive funding. The company confirmed the receipt on 10 August 2026, with the capital directed across its Artificial Intelligence, Extended Reality, Digital Health and Inclusive AI products.
The funding spans four active R&D grant programs and arrives without any share issuance or repayment obligation. For shareholders, that means fresh working capital supporting the company’s product roadmap without the dilution associated with an equity raise.
The company stated the funds will be used within its existing product roadmap and to expand collaboration potential, while improving the working capital position.
When big ASX news breaks, our subscribers know first
Where the money goes — four innovation projects
The $1.2 million supports four distinct technology domains: Inclusive AI and Sign Language translation, Cultural and Museum AI, Immersive Heritage Visualisation, and AI-powered Digital Health Rehabilitation. Each program feeds directly into the company’s commercial platforms rather than standalone academic research.
According to the company, these projects sit within the existing product roadmap and are designed to expand collaboration potential. The portfolio below details each program, its focus, and the research partners involved.
| Project | Focus Area | What It Does | Key Partners |
|---|---|---|---|
| L4ALL | Inclusive AI / Sign Language | AI translation of multimedia into Sign Language via Text-to-LIS and Formal SignWriting (FSW) | Mediavoice, ITCentric, Università Uninettuno, CNR LACAM |
| URGO ISI | Cultural / Museum AI | Adaptive conversational AI platform for museums, managing visitor interactions across cultural backgrounds | University College London (UCL), CNR, University of Milano-Bicocca, Oversonic Robotics |
| AVATART Calabria | Immersive Heritage / XR | AI-powered 3D avatars and holographic heritage visualisation | University of Calabria, Stark S.r.l. |
| OMNIREHAB | Digital Health / AI Rehabilitation | Remote rehabilitation combining Motion Capture and XR for home-based cognitive and physical recovery (Vection acts as project coordinator) | Two healthcare cooperatives operating in Tuscany |
Notably, Vection acts as project coordinator for OMNIREHAB, taking a lead role in the digital health rehabilitation program rather than a supporting position.
Why non-dilutive R&D funding matters to investors
These grants are awarded on the achievement of independently evaluated milestones, using criteria that reflect a high level of innovation capability in AI and XR development. Receiving the cash therefore acts as a formal external assessment that Vection’s work meets the required standards.
The company noted this is significant beyond the funding amount, describing it as validation of the strategic direction and quality of execution across its Research and Development investments.
Why this structure is favourable for shareholders:
-
No new shares issued, meaning no dilution
-
No repayment obligation
-
Improves the working capital position
-
Externally validates R&D milestones at an international level
How the programs strengthen Vection’s core platforms
The four programs are aligned with three core product platforms: Algho AI (conversational and multimodal AI), INTEGRATEDXR® (immersive reality), and Vection’s accessibility and phygital hardware capabilities. The programs address how AI communicates with sign language users, adapts to museum visitors, brings heritage to life through immersive technology, and supports home-based rehabilitation.
According to the company, some activities integrate directly into Algho AI and IntegratedXR, while others generate standalone intellectual property. The international research partnerships, including UCL, CNR, the University of Milano-Bicocca, the University of Calabria and Università Uninettuno, bring domain expertise that the company states it would otherwise take significantly longer and greater cost to develop independently.
Algho AI platform deployments across healthcare, luxury fashion, airport accessibility and security in Q4 FY26 show the commercial traction these R&D programs are designed to sustain, with the Sorint accessibility system already independently serving 97% of disabled passengers at Bergamo Caravaggio International Airport.
Gianmarco Biagi, Managing Director and Executive Chairman
“The achievement of the milestones that led to this funding confirmation demonstrates the high value of Vection’s development capabilities and confirms that the work being undertaken meets independently assessed standards, including at an international level. These four programs span several areas of our technology roadmap: inclusive AI, cultural engagement, immersive cultural heritage visualisation and digital health rehabilitation. The technologies and capabilities we are developing will be integrated into Algho AI and IntegratedXR, while other activities will generate standalone intellectual property.”
“Vection enters FY27 as a commercially self-sustaining business with positive operating cash flow and a very large sales pipeline. The Research and Development programs we are advancing through a combination of Vection’s own investment and government funding are how we ensure that the platform we are commercialising today continues to develop the capabilities our clients will require tomorrow.”
What comes next for Vection
The company plans to deploy the funds within its existing product roadmap, aiming to develop the capabilities its clients will require in the future. Management stated that its R&D programs are advanced through a combination of Vection’s own investment and government funding.
For investors, the update combines three elements: non-dilutive capital that carries no repayment or dilution cost, a commercial base the company describes as self-sustaining with positive operating cash flow, and international R&D validation. Together, these point to capability growth funded partly by third parties rather than shareholders alone.
The Retelit reference AI designation, which positions Algho as the platform for all AI services delivered across a 4,500-plus enterprise client network in Italy, illustrates the scale of commercial opportunity the company is building toward through both its direct sales activity and its ongoing R&D investment.
Don’t Miss the Next ASX Tech Winner
Big News Blast delivers FREE breaking ASX tech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.